Social Media Ideas for Gsk

GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript

GSK plans more than 1,200 job cuts in Belgium

<![CDATA[GSK Advances mRNA Flu Vaccine to Phase III ]]>

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

<![CDATA[Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Part...

GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over cur...

GSK: Still One Of My Top Healthcare Picks

GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed f...

Re-entering the Dragon: GSK returns to China after 12 years in blood cancer drug push

What a difference 12 years make. In 2014 GlaxoSmithKline was fined £300m by a Chinese court for running a 'massive bribery network'.

GSK to Invest $800 Million in Pennsylvania Biologics Expansion

GSK plans to invest more than $800 million in its Upper Merion, Pennsylvania, site, adding drug manufacturing, research, and quality testing facilities.

GSK plans to cut up to 1,217 jobs in Belgium - report

GSK to invest $800M on Pennsylvania expansion

The biopharmaceutical maker plans to establish a manufacturing hub with a quality control lab and plant for technology and process development. It is expected to create 300 jobs.

<![CDATA[Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targ...

Trading below levels seen 25 years ago, what on earth’s going on with the GSK share price?

Harvey Jones backed the GSK share price to spring into life a couple of years ago, but it's still struggling to make headway. Why isn't it doing better? The post Trading below leve...

GSK Backs Varaha Regenerative Agriculture Credits

GSK has committed to carbon credits from an Indian regenerative agriculture project as the pharmaceutical group expands its use of nature-based climate solutions. The eight-year pu...

GSK’s Pivotal Test for mRNA Flu Vaccine Aims to Show Two Targets Are Better Than One

GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna’s r...

Vaccine production site in Dresden to close after 115 years

Vaccine production in Germany's Dresden is set to end after 115 years, with pharmaceutical group GlaxoSmithKline (GSK) announcing plans on Thursday to close its site in the eastern...

<![CDATA[Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engag...

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>

Why is everybody suddenly buying GSK shares ahead of Rolls-Royce and SpaceX?

Harvey Jones is fascinated to see GSK shares are suddenly the most purchased stock of all, and wonders what's behind its sudden popularity. The post Why is everybody suddenly buyin...

<![CDATA[Where GLP-1 Development May be Headed]]>

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.